[COVID-19: epidemiology and mutations : An update].

4区 医学 Q3 Medicine
Radiologe Pub Date : 2021-10-01 Epub Date: 2021-09-20 DOI:10.1007/s00117-021-00909-0
Christoph J Hemmer, M Löbermann, E C Reisinger
{"title":"[COVID-19: epidemiology and mutations : An update].","authors":"Christoph J Hemmer, M Löbermann, E C Reisinger","doi":"10.1007/s00117-021-00909-0","DOIUrl":null,"url":null,"abstract":"<p><p>Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can enhance the spread and the infectiousness and decrease the protective effect of antibodies present after infection, vaccination or antibody treatment. The alpha variant (B.1.1.7), first seen in Kent/United Kingdom, has increased the R‑value and therefore the infectiousness by 75%; however, the effectiveness of the vaccines against SARS-CoV‑2 available in Germany seems to be only slightly impaired by these mutations. In the case of the beta variant (B.1.351), first described in South Africa, the neutralization ability of antibodies towards SARS-CoV‑2 is decreased. The monoclonal antibodies bamlanivimab and etesivimab, which are used therapeutically, are ineffective. The AstraZeneca vaccine offers almost no protection against mild or moderate disease caused by the beta variant. The gamma variant (P.1 or B.1.1.28.1), which was first found in Brazil, is probably 1.7-2.6 times more transmissible than previous virus strains circulating in Brazil. In addition to the infectiousness, the mortality risk of the gamma variant also seems to be increased between 1.2 and 1.9-fold in adults and between 5 and 8-fold in young persons. The delta variant (B.1.617), first described in India, is now dominant in most countries. It is 50% more infectious than the alpha variant, and the protective effect of vaccinations against symptomatic disease can be decreased (Biontech: delta variant 88%, alpha variant 93.7%; AstraZeneca: delta variant 67%, alpha variant 74.5%). Furthermore, the course of the disease with the delta variant is often more severe than with the wild type. Disease courses with the delta variant are less severe in vaccinated than in nonvaccinated persons, and fatal outcomes are substantially rarer. A high vaccination rate is essential in order to approach herd immunity and to bring the pandemic under control. Even where the protective effect towards mild or moderate disease is decreased, as a rule, vaccination still offers excellent protection against life-threatening and fatal disease courses.</p>","PeriodicalId":54513,"journal":{"name":"Radiologe","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450702/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiologe","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00117-021-00909-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/9/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can enhance the spread and the infectiousness and decrease the protective effect of antibodies present after infection, vaccination or antibody treatment. The alpha variant (B.1.1.7), first seen in Kent/United Kingdom, has increased the R‑value and therefore the infectiousness by 75%; however, the effectiveness of the vaccines against SARS-CoV‑2 available in Germany seems to be only slightly impaired by these mutations. In the case of the beta variant (B.1.351), first described in South Africa, the neutralization ability of antibodies towards SARS-CoV‑2 is decreased. The monoclonal antibodies bamlanivimab and etesivimab, which are used therapeutically, are ineffective. The AstraZeneca vaccine offers almost no protection against mild or moderate disease caused by the beta variant. The gamma variant (P.1 or B.1.1.28.1), which was first found in Brazil, is probably 1.7-2.6 times more transmissible than previous virus strains circulating in Brazil. In addition to the infectiousness, the mortality risk of the gamma variant also seems to be increased between 1.2 and 1.9-fold in adults and between 5 and 8-fold in young persons. The delta variant (B.1.617), first described in India, is now dominant in most countries. It is 50% more infectious than the alpha variant, and the protective effect of vaccinations against symptomatic disease can be decreased (Biontech: delta variant 88%, alpha variant 93.7%; AstraZeneca: delta variant 67%, alpha variant 74.5%). Furthermore, the course of the disease with the delta variant is often more severe than with the wild type. Disease courses with the delta variant are less severe in vaccinated than in nonvaccinated persons, and fatal outcomes are substantially rarer. A high vaccination rate is essential in order to approach herd immunity and to bring the pandemic under control. Even where the protective effect towards mild or moderate disease is decreased, as a rule, vaccination still offers excellent protection against life-threatening and fatal disease courses.

[COVID-19:流行病学和突变:最新进展]。
严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)的变异可加强传播和传染性,并降低感染、接种疫苗或抗体治疗后抗体的保护作用。首先出现在肯特郡/英国的阿尔法变异体(B.1.1.7)增加了 75% 的 R 值,因此感染性也增加了 75%;然而,德国现有的 SARS-CoV-2 疫苗的有效性似乎只受到这些变异体的轻微影响。在南非首次发现的贝塔变异体(B.1.351)的情况下,抗体对 SARS-CoV-2 的中和能力下降。用于治疗的单克隆抗体 bamlanivimab 和 etesivimab 无效。阿斯利康(AstraZeneca)公司的疫苗几乎不能预防由β变体引起的轻度或中度疾病。γ变种(P.1 或 B.1.1.28.1)首次在巴西发现,其传播性可能是以前在巴西流行的病毒株的 1.7-2.6 倍。除传染性外,γ变种的死亡风险在成人中似乎也增加了 1.2 至 1.9 倍,在年轻人中增加了 5 至 8 倍。德尔塔变体(B.1.617)最早在印度被描述,目前在大多数国家占主导地位。它比α变体的传染性高 50%,接种疫苗后对无症状疾病的保护效果会降低(Biontech:δ变体 88%,α变体 93.7%;AstraZeneca:δ变体 67%,α变体 74.5%)。此外,δ变体的病程往往比野生型更严重。与未接种疫苗的人相比,接种δ变异株的人的病程较轻,致命的结果也更为罕见。高疫苗接种率对于接近群体免疫和控制大流行至关重要。一般来说,即使对轻度或中度疾病的保护作用降低,接种疫苗仍能很好地预防危及生命和致命的疾病。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Radiologe
Radiologe 医学-核医学
CiteScore
1.10
自引率
0.00%
发文量
61
审稿时长
6-12 weeks
期刊介绍: Der Radiologe is an internationally recognized journal dealing with all aspects of radiology and serving the continuing medical education of radiologists in clinical and practical environments. The focus is on x-ray diagnostics, angiography computer tomography, interventional radiology, magnet resonance tomography, digital picture processing, radio oncology and nuclear medicine. Comprehensive reviews on a specific topical issue focus on providing evidenced based information on diagnostics and therapy. Freely submitted original papers allow the presentation of important clinical studies and serve the scientific exchange. Review articles under the rubric ''Continuing Medical Education'' present verified results of scientific research and their integration into daily practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信